We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Factors influencing agreement of breast cancer luminal molecular subtype by Ki67 labeling index between core needle biopsy and surgical resection specimens.
- Authors
Tendl-Schulz, Kristina A.; Rössler, Fabian; Wimmer, Philipp; Heber, Ulrike M.; Mittlböck, Martina; Kozakowski, Nicolas; Pinker, Katja; Bartsch, Rupert; Dubsky, Peter; Fitzal, Florian; Filipits, Martin; Eckel, Fanny Carolina; Langthaler, Eva-Maria; Steger, Günther; Gnant, Michael; Singer, Christian F.; Helbich, Thomas H.; Bago-Horvath, Zsuzsanna
- Abstract
Reliable determination of Ki67 labeling index (Ki67-LI) on core needle biopsy (CNB) is essential for determining breast cancer molecular subtype for therapy planning. However, studies on agreement between molecular subtype and Ki67-LI between CNB and surgical resection (SR) specimens are conflicting. The present study analyzed the influence of clinicopathological and sampling-associated factors on agreement. Molecular subtype was determined visually by Ki67-LI in 484 pairs of CNB and SR specimens of invasive estrogen receptor (ER)–positive, human epidermal growth factor (HER2)–negative breast cancer. Luminal B disease was defined by Ki67-LI > 20% in SR. Correlation of molecular subtype agreement with age, menopausal status, CNB method, Breast Imaging Reporting and Data System imaging category, time between biopsies, type of surgery, and pathological tumor parameters was analyzed. Recurrence-free survival (RFS) and overall survival (OS) were analyzed using the Kaplan–Meier method. CNB had a sensitivity of 77.95% and a specificity of 80.97% for identifying luminal B tumors in CNB, compared with the final molecular subtype determination after surgery. The correlation of Ki67-LI between CNB and SR was moderate (ROC-AUC 0.8333). Specificity and sensitivity for CNB to correctly define molecular subtype of tumors according to SR were significantly associated with tumor grade, immunohistochemical progesterone receptor (PR) and p53 expression (p < 0.05). Agreement of molecular subtype did not significantly impact RFS and OS (p = 0.22 for both). The identified factors likely mirror intratumoral heterogeneity that might compromise obtaining a representative CNB. Our results challenge the robustness of a single CNB-driven measurement of Ki67-LI to identify luminal B breast cancer of low (G1) or intermediate (G2) grade.
- Subjects
CORE needle biopsy; SURGICAL excision; BREAST cancer; EPIDERMAL growth factor; DEMETHYLATION; SURGICAL robots; PROGESTERONE receptors
- Publication
Virchows Archiv: European Journal of Pathology, 2020, Vol 477, Issue 4, p545
- ISSN
0945-6317
- Publication type
Article
- DOI
10.1007/s00428-020-02818-4